Kaleido Biosciences, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Kaleido Biosciences, Inc. - overview
Established
2015
Location
Lexington, MA, US
Primary Industry
Biotechnology
About
Kaleido Biosciences, Inc. is focused on developing innovative solutions in the life sciences and healthcare sectors, particularly through advanced platforms that enhance clinical trials, patient engagement, and data management. Kaleido Biosciences, Inc. was founded in 2015 and is headquartered in Lexington, US.
The company is engaged in providing innovative platforms for clinical trials and patient engagement. In February 2019, Kaleido raised USD 75 mn in an IPO, selling shares on NASDAQ. The most recent funding round was a Private Placement, where USD 60. 40 mn was raised in February 2021, following which the total amount raised by the company is USD 60.
40 mn. The current CEO is Daniel Menichella. Kaleido provides advanced platforms designed to streamline clinical trials and enhance patient engagement. Their solutions facilitate data management and address end-use cases such as drug development acceleration and effective patient recruitment.
The company serves pharmaceutical and biotechnology firms, primarily in North America and Europe, ensuring compliance and operational efficiency. In the most recent year, 2021, Kaleido reported a revenue of USD 1. 10 mn with an EBITDA of USD -84. 60 mn.
Kaleido's strategy for future growth includes the development of new product offerings aimed at enhancing clinical trial management and patient engagement. They are targeting expansion into additional markets in North America and Europe, with plans to leverage the recent funding of USD 60. 40 mn to support these initiatives. However, in April 2022, Kaleido announced the discontinuation of operations, which may affect these growth plans.
Current Investors
Flagship Pioneering
Primary Industry
Biotechnology
Sub Industries
Molecular Science, Genetics & Gene Therapy, Epidemiology, Pharmaceutical Research & Development
Website
www.kaleido.com
Company Stage
Ceased Operations
Total Amount Raised
Subscriber access only
Kaleido Biosciences, Inc. - timeline of key events
Kaleido Biosciences, Inc. - financials
| Fiscal Year Ended | Dec 31, 2018 | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 |
|---|---|---|---|---|
| Revenue (USD) | - | - | - | - |
| % Revenue Growth (YoY) | - | - | - | - |
| EBITDA (USD) | (61,100,000) | - | - | - |
| Operating Income (USD) | (61,900,000) | - | - | - |
| Operating Margin | - | - | - | - |
| % EBITDA Margin | - | - | - | - |
| NET Income (USD) | (61,700,000) | - | - | - |
| % Net Margin | - | - | - | - |
Kaleido Biosciences, Inc. - employee data
Kaleido Biosciences, Inc. - key contacts
| Name | Position | Start Date | End Date | Vcard | Bio | ||
|---|---|---|---|---|---|---|---|
| Board Member | BM |
BM Board Member
Want to see more?
Request a demo for full access to this profile
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.